The estimated Net Worth of Lorin Randall is at least $183 mil dollars as of 6 March 2018. Mr. Randall owns over 10,000 units of Acorda Therapeutics Inc stock worth over $6,600 and over the last 19 years he sold ACOR stock worth over $38,042. In addition, he makes $137,898 as Independent Director at Acorda Therapeutics Inc.
Sign up
Mr. Randall ACOR stock SEC Form 4 insiders trading
Lorin has made over 10 trades of the Acorda Therapeutics Inc stock since 2009, according to the Form 4 filled with the SEC. Most recently he sold 1,904 units of ACOR stock worth $38,042 on 26 November 2018.
The largest trade he's ever made was exercising 15,000 units of Acorda Therapeutics Inc stock on 18 August 2014 worth over $20,250. On average, Lorin trades about 1,545 units every 74 days since 2006. As of 6 March 2018 he still owns at least 10,000 units of Acorda Therapeutics Inc stock.
You can see the complete history of Mr. Randall stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Lorin Randall biography
Lorin Jeffry Randall serves as Independent Director of the Company. Mr. Randall, a financial consultant, was Senior Vice President and Chief Financial Officer of Eximias Pharmaceutical Corporation, a development-stage drug development company, from 2004 to 2006. From 2002 to 2004, Mr. Randall served as Senior Vice President and Chief Financial Officer of i-STAT Corporation, a publicly-traded manufacturer of medical diagnostic devices that was acquired by Abbott Laboratories in 2004. From 1995 to 2001, Mr. Randall was Vice President and Chief Financial Officer of CFM Technologies, Inc., a publiclytraded manufacturer of semiconductor manufacturing equipment. He currently serves on the boards of directors of Athersys, Inc. where he serves as Chairperson of the Audit Committee, Chairperson of the Compensation Committee and member of the Nominations Committee. In addition, within the last five years, he previously served on the boards of directors of Aurinia Pharmaceuticals Inc., Nanosphere, Inc. and Tengion, Inc. Mr. Randall received a B.S. in accounting from The Pennsylvania State University and an M.B.A. from Northeastern University. As a former Chief Financial Officer of a number of publicly-traded companies, Mr. Randall possesses financial acumen acquired through working experience, including an understanding of financial matters and the preparation and analysis of financial statements.
What is the salary of Lorin Randall?
As the Independent Director of Acorda Therapeutics Inc, the total compensation of Lorin Randall at Acorda Therapeutics Inc is $137,898. There are 9 executives at Acorda Therapeutics Inc getting paid more, with Ron Cohen having the highest compensation of $2,039,560.
How old is Lorin Randall?
Lorin Randall is 76, he's been the Independent Director of Acorda Therapeutics Inc since 2006. There are no older and 17 younger executives at Acorda Therapeutics Inc.
What's Lorin Randall's mailing address?
Lorin's mailing address filed with the SEC is 2 BLUE HILL PLAZA, 3RD FLOOR, PEARL RIVER, NY, 10965.
Insiders trading at Acorda Therapeutics Inc
Over the last 19 years, insiders at Acorda Therapeutics Inc have traded over $155,173,492 worth of Acorda Therapeutics Inc stock and bought 1,139,691 units worth $17,085,546 . The most active insiders traders include Capital Management Lp Scopi..., Ian F Smith, eRon Cohen. On average, Acorda Therapeutics Inc executives and independent directors trade stock every 19 days with the average trade being worth of $19,752. The most recent stock trade was executed by Ron Cohen on 16 March 2023, trading 20,156 units of ACOR stock currently worth $12,497.
What does Acorda Therapeutics Inc do?
acorda therapeutics is a publicly traded (nasdaq: acor) biotechnology company whose mission is to develop therapies that restore neurological function and improve the lives of people with neurological disorders. we started our company in 1995 as a network of scientists, physicians and business people with a common belief that sharing ideas and information could lead to innovative medical advances for people with neurological disorders. we have since evolved into a commercial-stage biotechnology company, successfully developing and commercializing important therapies that advance the care of people affected by neurological conditions. we achieve our goals by: • investing in research and development • collaborating closely with the patient, medical and scientific communities • retaining employees with compassion and commitment acorda has been voted one of the best companies to work for in new york for the past five years in a row, as a result of our dynamic environment, strong corporate
What does Acorda Therapeutics Inc's logo look like?
Complete history of Mr. Randall stock trades at Acorda Therapeutics Inc e Athersys Inc
Acorda Therapeutics Inc executives and stock owners
Acorda Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Ron Cohen,
President,Chief Executive Officer, Director -
Dr. Ron Cohen M.D.,
Founder, CEO, Pres & Director -
Burkhard Blank,
Chief Medical Officer and Head of R&D -
Lauren Sabella,
Chief Commercial Officer -
David Lawrence,
Chief Business Operations, Principal Accounting Officer -
Dr. Burkhard Blank M.D.,
Consultant -
Lauren M. Sabella,
Chief Operating Officer -
Peder Jensen,
Independent Director -
John Kelley,
Non-Executive Independent Chairman of the Board -
Lorin Randall,
Independent Director -
Sandra Panem,
Independent Director -
Barry Greene,
Independent Director -
Catherine Strader,
Independent Director -
Neil S. Belloff Esq.,
Gen. Counsel -
Michael A. Gesser M.B.A.,
Chief Financial Officer -
Dr. Wise Young M.D., Ph.D.,
Special Scientific Advisor -
Kerry M. Clem,
Chief Commercial Officer -
Robert Morales,
Interim Principal Accounting Officer, Principal Financial Officer, VP of Fin. & Controller -
Peter S. Carbone,
Exec. VP of Quality -
Dr. Andrew R. Blight,
Chief Scientific Officer Emeritus -
Denise J. Duca,
Exec. VP of HR -
Tierney Saccavino,
Exec. VP of Corp. Communications -
Andrew Mayer J.D.,
Sr. VP, Deputy Gen. Counsel & Corp. Sec. -
Felicia Vonella,
VP of Investor Relations -
Ian F Smith,
Director -
Richard P. Batycky,
Chief Tech. Off. & Site Head -
Steven M Rauscher,
Director -
Capital Management Lp Scopi...,
-
Kerry M Clem,
Chief Commercial Officer -
Wise Young,
Director -
Thomas Wessel,
Chief Medical Officer -
Andrew A. Hindman,
Chief Business Dev. Officer -
Barclay A Phillips,
Director -
Capital Investments Ltd.Rid...,
-
Mark R E Pinney,
Director -
Michael Steinmetz,
Director -
Standish Fleming,
Director -
John H Friedman,
Director -
Mary Fisher,
Chief Operating Officer -
Michael W Rogers,
Chief Financial Officer -
Enrique J. Carrazana,
Chief Medical Officer -
Jane Wasman,
President, Intl and GC -
Robert Morales,
Interim PAO & PFO -
John Varian,
Director -
Michael A Gesser,
Chief Financial Officer -
Thomas M. Burns,
Director -
Neil S. Belloff,
General Counsel and Corp Secy